RT Journal Article
SR Electronic
T1 Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002973
DO 10.1136/jitc-2021-002973
VO 9
IS 8
A1 Leighl, Natasha B
A1 Redman, Mary W
A1 Rizvi, Naiyer
A1 Hirsch, Fred R
A1 Mack, Philip C
A1 Schwartz, Lawrence H
A1 Wade, James L
A1 Irvin, William J
A1 Reddy, Sreekanth C
A1 Crawford, Jeffrey
A1 Bradley, Jeffrey D
A1 Stinchcombe, Thomas E
A1 Ramalingam, Suresh S
A1 Miao, Jieling
A1 Minichiello, Katherine
A1 Herbst, Roy S
A1 Papadimitrakopoulou, Vassiliki A
A1 Kelly, Karen
A1 Gandara, David R
YR 2021
UL http://jitc.bmj.com/content/9/8/e002973.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.